Results 151 to 160 of about 14,520 (202)

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer. [PDF]

Clin Cancer Res
Jhaveri K, Loi S, Hamilton E, Schmid P, Anders CK, Testa L, Wildiers H, Tseng LM, Lu YS, Park YH, Im SA, Chen SC, Young RR, Lloyd C, Wrona M, Zhang C, Carroll D, André F.   +17 more
europepmc   +1 more source

Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer. [PDF]

Clin Pharmacol Ther
Chigutsa E, Chapman SC, Turner PK.
europepmc   +1 more source

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial. [PDF]

Breast Cancer Res Treat
Hörner M, Tretschock LM, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, Amann N, Cieslik JP, Dannehl D, Deutsch TM, Dimpfl M, Ehlert M, Eichstädt K, Englisch A, Köpke MB, Krückel A, Link T, Müller A, Reinhardt K, Roth J, Schäffler H, Sych L, Tegeler CM, Wichmann C, Banys-Paluchowski M, Princk H, Rody A, Brucker SY, Ditsch N, Ettl J, Fehm T, Hack CC, Hadji P, Hein A, Janni WW, Kolberg HC, Lüftner D, Lux MP, Müller V, Schneeweiss A, Taran FA, Tesch H, Wallwiener D, Marmé F, Seitz S, Belleville E, Hartkopf A, Michel LL, Wallwiener M, Fasching PA, Tauber N.   +51 more
europepmc   +1 more source

Estradiol levels in women with hormone receptor-positive advanced breast cancer on fulvestrant therapy. [PDF]

Oncologist
Dai S, Wen Y, Wu X, Wang X, Yuan Z, Xu F, Xie X, Xia W, Wang S, Shi Y, Liu P, Zheng Q, Tang J, An X, Huang J, Chen M, Zhong Y, Bi X, Yang Y, Xue C.   +19 more
europepmc   +1 more source

Analysis of the Frequency and Associated Factors of Skin Toxicity in Patients Receiving Ribociclib-Based Therapy for Metastatic Breast Cancer. [PDF]

Cancers (Basel)
Kim E, Lim Y, Ham A, Kim HG, Lee JW, Lee JH, Woo J, Lim W, Moon BI, Ahn SH, Lee HA, Lee KE.   +11 more
europepmc   +1 more source

Real-world treatment patterns and sequencing in patients with advanced / metastatic HR+/HER2- breast cancer in Europe and the United States. [PDF]

Breast
Mahtani R, Korytowsky B, Rose CG, Jakobsson M, Cappelleri J, Lewis K, Lambert A, Hammond C, Criscitiello C.   +8 more
europepmc   +1 more source

Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer. [PDF]

Breast Cancer Res
Lei L, Bhave M, Kalinsky K, Gandhi S.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Fulvestrant

Drugs, 2012
Jamie D Croxtall, Kate Mckeage, Mckeage Kate   +2 more
exaly   +4 more sources

Fulvestrant

Drugs, 2001
Fulvestrant is a 7alpha-alkylsulphinyl analogue of estradiol that competes with endogenous estrogen for binding to the estrogen receptor. Once bound to the receptor, fulvestrant attenuates receptor dimerisation, effecting a rapid degradation of the estrogen receptor protein and inhibition of transcription.
M, Curran, L, Wiseman
  +6 more sources